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Introduction
============

In 1942, Conrad Hal Waddington was the first to use the Greek word "epigenesis", to describe how cells differentiated, and thus epigenetics was coined to mean \"the causal interactions between genes and their products which bring the phenotype into being\" \[[@REF1]\]. But it was not until the 1970s when the contemporary definition emerged as "a hereditable change in gene expression that occurred without a change in the DNA sequence" \[[@REF2]\]. Broadly speaking, as it applies to modern cancer biology, epigenetics now refers to regulatory mechanisms of DNA transcription that affect gene expression of which DNA methylation is the most widely studied. The relative role of epigenetics in cancer has been attributed to the observation in 1983 by two laboratories that most cancer DNA has fewer methyl groups than non-cancer DNA \[[@REF3]-[@REF5]\]. In one of these studies, Feinberg and Vogelstein showed that DNA methylation was linked to tissue-specific gene silencing in cancer, by finding that a substantial proportion of CpG islands were methylated in normal tissues were unmethylated in cancer cells \[[@REF3]\].

Citation analysis is a systematic approach for identifying scientific publications that have a high impact in the scientific or medical community measuring high-impact papers and how they have shaped scientific disciplines \[[@REF6]\]. For this purpose, the Institute for Scientific Information collects citation counts for academic journals in the Science Citation Index. Although bibliometric analyses have been performed in the past on cancer and genomics, little is known about the most frequently cited articles specifically related to cancer epigenetics \[[@REF6]-[@REF10]\]. Therefore, the purpose of this study is to use citation count to identify those papers in the scientific literature that have made key contributions in the field of cancer epigenetics and identify key driving forces behind future investigations.

Materials and methods
=====================

The Thomson Reuters Web of Science (WoS) database was used to query for citations of all articles relevant to cancer epigenetics. The basic search tool was selected, the keyword search for the topic to identify the articles of interest was specified as: "(epigenetic OR epigenomic OR methylation OR hypermethylation OR CpG island OR chromatic remodeling OR histone modification OR RNA interference OR gene silencing OR promoter regions OR chromatin assembly and disassembly OR liquid biopsy OR molecular OR biomolecular) AND (cancer OR neoplasm)". The following search parameters were used: 1) articles published in the years 1980-2018 (since the word \"epigenetics\" was conceived in 1980); 2) all languages; 3) within the Science Citation Index Expanded. The results were carefully reviewed, and only those relevant to cancer epigenetics were selected. All review articles were excluded from the list. The top 100 articles by the number of citations that matched the search criteria were then further analyzed, and the title, first author, journal, and year of publication, number of citations, country, and the institution of origin were recorded. The articles retrieved were sorted in descending order in terms of times cited, and the number of citations per year was calculated.

Results
=======

Our query retrieved 234,679 papers (Figure [1](#FIG1){ref-type="fig"}).

![Number of publications per year retrieved from the Thomson Reuters Web of Science with the keyword search described in methods](cureus-0012-00000007623-i01){#FIG1}

The top 100 articles related to "cancer epigenetics" were identified by the number of times they were cited (Table [1](#TAB1){ref-type="table"}).

###### The top 100 most cited articles in cancer epigenetics ranked by number of times cited

CY - number of citations per year; WoS - Web of Knowledge

Citations corresponding to WoS rank are located in appendices.

  ---------- ---------------------- ------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- ---------- ---------
  WoS Rank   Authors                Year   Article title                                                                                                                                                                                       Total number of citations   CY index   CY rank
  1          Golub et al.           1999   Molecular classification of cancer: class discovery and class prediction by gene expression monitoring                                                                                              7124                        375        6
  2          Alizadeh et al.        2000   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling                                                                                                             6045                        336        13
  3          Herman et al.          1996   Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands                                                                                                                   4600                        209        26
  4          Barski et al.          2007   High-resolution profiling of histone methylations in the human genome                                                                                                                               3849                        350        10
  5          Hegi et al.            2005   MGMT gene silencing and benefit from temozolomide in glioblastoma                                                                                                                                   3394                        261        21
  6          Chin et al.            2008   Comprehensive genomic characterization defines human glioblastoma genes and core pathways                                                                                                           3359                        336        12
  7          Cerami et al.          2012   The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data                                                                                               3354                        559        2
  8          Stupp et al.           2009   Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial   3252                        361        8
  9          Muzny et al.           2012   Comprehensive molecular characterization of human colon and rectal cancer                                                                                                                           3157                        526        3
  10         Verhaak et al.         2010   Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1                                                   2891                        361        7
  11         Bell et al.            2011   Integrated genomic analyses of ovarian carcinoma                                                                                                                                                    2725                        389        5
  12         Gupta et al.           2010   Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis                                                                                                                  2637                        330        15
  13         Forner et al.          2012   Hepatocellular carcinoma                                                                                                                                                                            2427                        405        4
  14         Travis et al.          2011   International association for the study of lung cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of lung adenocarcinoma                 2225                        318        17
  15         Yanaihara et al.       2006   Unique microRNA molecular profiles in lung cancer diagnosis and prognosis                                                                                                                           2169                        181        27
  16         Curtis et al.          2012   The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups                                                                                                         1911                        319        16
  17         Neve et al.            2006   A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes                                                                                                     1828                        152        30
  18         Nielsen et al.         2004   Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma                                                                                            1731                        124        42
  19         Hammerman et al.       2012   Comprehensive genomic characterization of squamous cell lung cancers                                                                                                                                1731                        289        19
  20         Toyota et al.          1999   CpG island methylator phenotype in colorectal cancer                                                                                                                                                1701                        90         58
  21         Takamizawa et al.      2004   Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival                                                                                1695                        121        43
  22         Merlo et al.           1995   5\' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers                                                                    1671                        73         72
  23         Ley et al.             2013   Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia                                                                                                                           1656                        331        14
  24         Varambally et al.      2002   The polycomb group protein EZH2 is involved in progression of prostate cancer                                                                                                                       1625                        102        50
  25         Bhattacharjee et al.   2001   Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses                                                                                     1624                        96         52
  26         Esteller et al.        2001   A gene hypermethylation profile of human cancer                                                                                                                                                     1605                        94         55
  27         Meissner et al.        2008   Genome-scale DNA methylation maps of pluripotent and differentiated cells                                                                                                                           1538                        154        29
  28         Zhang et al.           2007   microRNAs as oncogenes and tumor suppressors                                                                                                                                                        1515                        138        36
  29         Kandoth et al.         2013   Mutational landscape and significance across 12 major cancer types                                                                                                                                  1506                        301        18
  30         Cameron et al.         1999   Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer                                                                                        1473                        78         66
  31         Clark et al.           1994   High sensitivity mapping of methylated cytosines.                                                                                                                                                   1464                        61         80
  32         Herman et al.          1998   Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma                                                                                                    1455                        73         71
  33         Bass et al.            2014   Comprehensive molecular characterization of gastric adenocarcinoma                                                                                                                                  1403                        351        9
  34         Collisson et al.       2014   Comprehensive molecular profiling of lung adenocarcinoma                                                                                                                                            1372                        343        11
  35         Brennan et al.         2013   The somatic genomic landscape of glioblastoma                                                                                                                                                       1367                        273        20
  36         Esteller et al.        2000   Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents                                                                                                  1360                        76         69
  37         Weinstein et al.       2013   The cancer genome atlas pan-cancer analysis project                                                                                                                                                 1293                        259        22
  38         Weber et al.           2007   Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome                                                                                           1289                        117        47
  39         Figueroa et al.        2010   Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation                                                            1280                        160        28
  40         Getz et al.            2013   Integrated genomic characterization of endometrial carcinoma                                                                                                                                        1273                        255        23
  41         Irizarry et al.        2009   The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores                                                                            1267                        141        35
  42         Herman et al.          1995   Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.                                                                         1241                        54         88
  43         Narita et al.          2003   Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence                                                                                                  1238                        83         64
  44         Herman et al.          1994   Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.                                                                                                                   1226                        51         91
  45         Swerdlow et al.        2016   The 2016 revision of the World Health Organization classification of lymphoid neoplasms                                                                                                             1201                        601        1
  46         Noushmehr et al.       2010   Identification of a CpG Island methylator phenotype that defines a distinct subgroup of glioma                                                                                                      1170                        146        32
  47         Kane et al.            1997   Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines                                         1164                        55         84
  48         Weisenberger et al.    2006   CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer                                                     1162                        97         51
  49         Weber et al.           2005   Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells                                                                 1087                        84         61
  50         Fraga et al.           2005   Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer                                                                                         1060                        82         65
  51         Fabbri et al.          2007   MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B                                                                                        1041                        95         54
  52         Orom et al.            2010   Long noncoding RNAs with enhancer-like function in human cells                                                                                                                                      1041                        130        39
  53         Kleer et al.           2003   EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells                                                                                      1014                        68         77
  54         Weinstein et al.       2014   Comprehensive molecular characterization of urothelial bladder carcinoma                                                                                                                            1014                        254        24
  55         Jahr et al.            2001   DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells                                                                 1005                        59         82
  56         Hudson et al.          2010   International network of cancer genome projects                                                                                                                                                     1000                        125        40
  57         Costello et al.        2000   Aberrant CpG-island methylation has non-random and tumour-type-specific patterns                                                                                                                    994                         55         85
  58         Gaudet et al.          2003   Induction of tumors in mice by genomic hypomethylation                                                                                                                                              993                         66         78
  59         Sharma et al.          2010   A Chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations                                                                                                                   968                         121        44
  60         Esteller et al.        1999   Inactivation of the DNA repair gene O-6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia                                               956                         50         92
  61         Zuber et al.           2011   RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia                                                                                                                      941                         134        37
  62         Iorio et al.           2007   MicroRNA signatures in human ovarian cancer                                                                                                                                                         937                         85         60
  63         Dweep et al.           2011   miRWalk - database: prediction of possible miRNA binding sites by \"walking\" the genes of three genomes                                                                                            936                         134        38
  64         Comijn et al.          2001   The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion                                                                                                 933                         55         86
  65         Issa et al.            1994   Methylation of the oestrogen receptor CpG island links aging and neoplasia in human colon.                                                                                                          925                         39         98
  66         Kosaka et al.          2010   Secretory mechanisms and intercellular transfer of microRNAs in living cells                                                                                                                        920                         115        48
  67         Saito et al.           2006   Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells                                                               917                         76         67
  68         Carroll et al.         2006   Genome-wide analysis of estrogen receptor binding sites                                                                                                                                             911                         76         68
  69         Valk et al.            2004   Prognostically useful gene-expression profiles in acute myeloid leukemia                                                                                                                            907                         65         79
  70         Weinstein et al.       1997   An information-intensive approach to the molecular pharmacology of cancer                                                                                                                           906                         43         95
  71         Kantarjian et al.      2006   Decitabine improves patient outcomes in myelodysplastic syndromes - resuits of a phase III randomized study                                                                                         899                         75         70
  72         Houseman et al.        2012   DNA methylation arrays as surrogate measures of cell mixture distribution                                                                                                                           896                         149        31
  73         Patel et al.           2014   Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma                                                                                                                   896                         224        25
  74         West et al.            2001   Predicting the clinical status of human breast cancer by using gene expression profiles                                                                                                             891                         52         90
  75         Turchinovich et al.    2011   Characterization of extracellular circulating microRNA                                                                                                                                              874                         125        41
  76         McCabe et al.          2012   EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations                                                                                                               861                         144        33
  77         Dammann et al.         2000   Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3                                                                                     855                         48         94
  78         Turcan et al.          2012   IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype                                                                                                                       854                         142        34
  79         Rhee et al.            2002   DNMT1 and DNMT3b cooperate to silence genes in human cancer cells                                                                                                                                   852                         53         89
  80         Lapointe et al.        2004   Gene expression profiling identifies clinically relevant subtypes of prostate cancer                                                                                                                849                         61         81
  81         Eckhardt et al.        2006   DNA methylation profiling of human chromosomes 6, 20 and 22                                                                                                                                         847                         71         73
  82         Bos et al.             2009   Genes that mediate breast cancer metastasis to the brain                                                                                                                                            847                         94         56
  83         Iliopoulos et al.      2009   An epigenetic switch involving NF-kappa B, lin28, let-7 microRNA, and IL6 links inflammation to cell transformation                                                                                 845                         94         57
  84         Bracken et al.         2006   Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions                                                                                                          842                         70         74
  85         Campo et al.           2011   The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications                                                                                          825                         118        45
  86         Chapman et al.         2011   Initial genome sequencing and analysis of multiple myeloma                                                                                                                                          824                         118        46
  87         Murakami et al.        2006   Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues                                                                                         815                         68         76
  88         Gregoretti et al.      2004   Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis                                                                                             806                         58         83
  89         Li et al.              2002   Causal relationship between the loss of RUNX3 expression and gastric cancer                                                                                                                         805                         50         93
  90         Ng et al.              2009   Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening                                                               794                         88         59
  91         Bibikova et al.        2011   High density DNA methylation array with single CpG site resolution                                                                                                                                  762                         109        49
  92         Yap et al.             2010   Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a                                                           760                         95         53
  93         Suzuki et al.          2004   Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer                                                                                                        758                         54         87
  94         Esteller et al.        2000   Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors                                                                                                              756                         42         96
  95         Schlesinger et al.     2007   Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer                                                                                              748                         68         75
  96         Shimono et al.         2009   Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells                                                                                                                  745                         83         62
  97         Doi et al.             2009   Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts                                  744                         83         63
  98         Esteller et al.        1999   Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients                                                                     741                         39         97
  99         Belinsky et al.        1998   Aberrant methylation of p16\[INK4a\] is an early event in lung cancer and a potential biomarker for early diagnosis                                                                                 723                         36         99
  100        Rainier et al.         1993   Relaxation of imprinted genes in human cancer.                                                                                                                                                      720                         29         100
  ---------- ---------------------- ------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- ---------- ---------

The articles on this top 100 list were cited between 7,124 times (article rank 1) and 720 times (article rank 100). Collectively, the top 100 articles have been cited 147,083 times with a median of 1,050 for each paper, and an interquartile range of 871 - 1610. The oldest article on the top 100 list was from 1993, and the most recent from 2016. In the period 1980-2018, the two most prolific years were 2006 and 2010, with nine articles each among the top 100 most cited articles. In terms of the number of citations per year, the top article had been cited 375 times per year (CY rank number 6). Likewise, the bottom article has been cited 29 times per year (CY rank number 100). A graph of time vs. publication output (Figure [1](#FIG1){ref-type="fig"}) indicates that the field of cancer epigenetics has had publications in the range 1994-2014. The most productive decade was from 2000 to 2009, producing 49 papers in the Top 100 (Table [2](#TAB2){ref-type="table"}).

###### Decade of publication of top 100 in cancer epigenetics

  ----------------------- -------------------------
  Decade of publication   No. of articles (n=100)
  1970-1979               0
  1980-1989               0
  1990-1999               13
  2000-2009               49
  2010-2019               27
  ----------------------- -------------------------

The top 100 most cited articles were published in 28 different journals, with the journal Nature contributing the most studies with 22 articles (Table [3](#TAB3){ref-type="table"}).

###### Journals of origin

  ------ ---------------------------------------------------------------------------------
  Rank   Journal
  1      Nature
  2      Nature Genetics
  3      Proceedings of the National Academy of Sciences of the United States of America
  4      Cancer Research
  4      Cell
  5      Cancer Cell
  6      New England Journal of Medicine
  6      Science
  7      Blood
  7      Molecular Cell
  7      Nucleic Acids Research
  8      BMC Bioinformatics
  8      Cancer
  8      Cancer Discovery
  8      Clinical Cancer Research
  8      Developmental Biology
  8      Genes Development
  8      Genomics
  8      Gut
  8      Journal of the National Cancer Institute
  8      Journal of Biological Chemistry
  8      Journal of Biomedical Informatics
  8      Journal of Molecular Biology
  8      Journal of Thoracic Oncology
  8      Lancet
  8      Lancet Oncology
  8      Nature Medicine
  8      Oncogene
  ------ ---------------------------------------------------------------------------------

Seventy-eight percent of the top 100 most cited papers originated in the United States (n=78). The next five countries with the highest number of articles were Germany (n=4), Switzerland (n=4), Japan (n=3), Spain (n=2), and United Kingdom (n=2). Australia, Belgium, Denmark, Israel, Netherlands, China, and South Korea had one article, each among the top 100. Among the 100 most cited papers, there were a total of 77 unique first authors. Collectively, the two authors with the largest number of articles on the top 100 list were Baylin SB and Herman JG with 26 and 20 papers, respectively (Table [4](#TAB4){ref-type="table"}). The next five authors that followed were Getz G, Laird PW, Meyerson M, Sander C, and Weisenberger DJ, each with 13, 12, 12, 12, and 12 articles, respectively.

###### Top five authors appearing in top 100 list

  ------ ----------------- -------------------------
  Rank   Author            No. of articles (n=100)
  1      Baylin SB         26
  2      Herman JG         20
  3      Getz G            13
  4      Laird PW          12
  4      Meyerson M        12
  4      Sander C          12
  4      Weisenberger DJ   12
  5      Ding L            11
  5      Hayes DN          11
  5      Lander ES         11
  5      Perou CM          11
  ------ ----------------- -------------------------

Among the top 100 cited papers, there were three clinical trials, two guidelines or society-based recommendations, 18 cancer classifications, 11 articles related to research tools or methods, 55 articles related to epigenetic cancer mechanism, nine papers related to epigenetic cancer markers/screening/diagnosis and five papers related to epigenetics and cancer treatment (Table [5](#TAB5){ref-type="table"}).

###### The top 100 most cited articled in cancer epigenetics categorized by review, clinical trials, guidelines of society-based recommendations, classifications, research tools/methods, epigenetic mechanisms, epigenetic markers/screening/diagnosis, and epigenetic cancer treatment

WoS - Web of Knowledge

Citations corresponding to WoS rank are located in appendices.

  ----------------------------------------------------- ---------------------- ------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------
  WoS citation rank                                     Authors                Year   Article title                                                                                                                                                                                       Total number of citations
  CLINICAL TRIALS (n=3)                                                                                                                                                                                                                                                                   
  5                                                     Hegi et al.            2005   MGMT gene silencing and benefit from temozolomide in glioblastoma                                                                                                                                   3394
  8                                                     Stupp et al.           2009   Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial   3252
  71                                                    Kantarjian et al.      2006   Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study                                                                                         899
  GUIDELINES OR SOCIETY-BASED RECOMMENDATIONS (n=3)                                                                                                                                                                                                                                       
  14                                                    Travis et al.          2011   International association for the study of lung cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of lung adenocarcinoma                 2225
  56                                                    Hudson et al.          2010   International network of cancer genome projects                                                                                                                                                     1000
  CLASSIFICATIONS (n=18)                                                                                                                                                                                                                                                                  
  1                                                     Golub et al.           1999   Molecular classification of cancer: class discovery and class prediction by gene expression monitoring                                                                                              7124
  2                                                     Alizadeh et al.        2000   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling                                                                                                             6045
  10                                                    Verhaak et al.         2010   Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1                                                   2891
  16                                                    Curtis et al.          2012   The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups                                                                                                         1911
  17                                                    Neve et al.            2006   A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes                                                                                                     1828
  18                                                    Nielsen et al.         2004   Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma                                                                                            1731
  20                                                    Toyota et al.          1999   CpG island methylator phenotype in colorectal cancer                                                                                                                                                1701
  23                                                    Ley et al.             2013   Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia                                                                                                                           1656
  25                                                    Bhattacharjee et al.   2001   Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses                                                                                     1624
  29                                                    Kandoth et al.         2013   Mutational landscape and significance across 12 major cancer types                                                                                                                                  1506
  35                                                    Brennan et al.         2013   The somatic genomic landscape of glioblastoma                                                                                                                                                       1367
  39                                                    Figueroa et al.        2010   Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation                                                            1280
  45                                                    Swerdlow et al.        2016   The 2016 revision of the World Health Organization classification of lymphoid neoplasms                                                                                                             1201
  46                                                    Noushmehr et al.       2010   Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma                                                                                                      1170
  48                                                    Weisenberger et al.    2006   CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer                                                     1162
  78                                                    Turcan et al.          2012   IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype                                                                                                                       854
  80                                                    Lapointe et al.        2004   Gene expression profiling identifies clinically relevant subtypes of prostate cancer                                                                                                                849
  85                                                    Campo et al.           2011   The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications                                                                                          825
  RESEARCH TOOLS/METHODS (n=11)                                                                                                                                                                                                                                                           
  3                                                     Herman et al.          1996   Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands                                                                                                                   4600
  4                                                     Barski et al.          2007   High-resolution profiling of histone methylations in the human genome                                                                                                                               3849
  7                                                     Cerami et al.          2012   The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data                                                                                               3354
  31                                                    Clark et al.           1994   High sensitivity mapping of methylated cytosines.                                                                                                                                                   1464
  37                                                    Weinstein et al.       2013   The cancer genome Atlas Pan-Cancer analysis project                                                                                                                                                 1293
  49                                                    Weber et al.           2005   Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells                                                                 1087
  63                                                    Dweep et al.           2011   miRWalk - database: prediction of possible miRNA binding sites by \"walking\" the genes of three genomes                                                                                            936
  70                                                    Weinstein et al.       1997   An information-intensive approach to the molecular pharmacology of cancer                                                                                                                           906
  72                                                    Houseman et al.        2012   DNA methylation arrays as surrogate measures of cell mixture distribution                                                                                                                           896
  75                                                    Turchinovich et al.    2011   Characterization of extracellular circulating microRNA                                                                                                                                              874
  91                                                    Bibikova et al.        2011   High density DNA methylation array with single CpG site resolution                                                                                                                                  762
  EPIGENETIC CANCER MARKERS/SCREENING/DIAGNOSIS (n=9)                                                                                                                                                                                                                                     
  15                                                    Yanaihara et al.       2006   Unique microRNA molecular profiles in lung cancer diagnosis and prognosis                                                                                                                           2169
  21                                                    Takamizawa et al.      2004   Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival                                                                                1695
  53                                                    Kleer et al.           2003   EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells                                                                                      1014
  55                                                    Jahr et al.            2001   DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells                                                                 1005
  69                                                    Valk et al.            2004   Prognostically useful gene-expression profiles in acute myeloid leukemia                                                                                                                            907
  74                                                    West et al.            2001   Predicting the clinical status of human breast cancer by using gene expression profiles                                                                                                             891
  90                                                    Ng et al.              2009   Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening                                                               794
  98                                                    Esteller et al.        1999   Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients                                                                     741
  99                                                    Belinsky et al.        1998   Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis                                                                                   723
  EPIGENETIC CANCER TREATMENT (n=5)                                                                                                                                                                                                                                                       
  5                                                     Hegi et al.            2005   MGMT gene silencing and benefit from temozolomide in glioblastoma                                                                                                                                   3394
  8                                                     Stupp et al.           2009   Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial   3252
  61                                                    Zuber et al.           2011   RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia                                                                                                                      941
  71                                                    Kantarjian et al.      2006   Decitabine improves patient outcomes in myelodysplastic syndromes - resuits of a phase III randomized study                                                                                         899
  76                                                    McCabe et al.          2012   EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations                                                                                                               861
  ----------------------------------------------------- ---------------------- ------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------

Discussion
==========

In this study, we sought to identify the most cited 100 articles regarding cancer epigenetics, to gain insight into the history and future directions of this rapidly growing scientific field.

The article that received the most citations on the top 100 list was "Molecular classification of cancer: class discovery and class prediction by gene expression monitoring" \[[@REF11]\]. This paper was cited 7,340 times, with an average of 408 citations per year since publication. At the time, the paper was notable for developing the first generalized approach for identifying new cancer classes by applying gene expression profiling to distinguish between acute myeloid leukemia (AML) versus acute lymphoblastic leukemia (ALL). This study marked the beginning of gene expression-based cancer therapy. Currently, the European LeukemiaNet classification in AML uses cytogenetic and molecular data to identify the AML prognostic groups \[[@REF12]-[@REF14]\].

Since the first epigenetic abnormality was identified in cancer cells in 1983, multiple advances led to improved knowledge in epigenetics and cancer \[[@REF3]-[@REF5]\]. DNA methylation has been defined as an example of epigenetic dysregulation in cancer, with both hypomethylation and hyper-methylation having significant roles. DNA hypomethylation can lead to gene activation, and it is linked to chromosomal instability \[[@REF15], [@REF16]\]. DNA hypermethylation has been associated with gene silencing as a tumor-suppressor silencing cancer mechanism given that it has been found when genes are rarely mutated but that are frequently DNA hypermethylated and silenced in cancer \[[@REF17]-[@REF20]\]. Histone modification is another epigenetic cancer-linked mechanism that controls chromatin structure \[[@REF21], [@REF22]\]. As a result, the detection of epigenetic changes, such as abnormal promoter CpG island DNA hypermethylation, has been studied as a potential biomarker strategy for assessing cancer risk, early detection, prognosis and predicting therapeutic responses \[[@REF23], [@REF24]\]. The list of potential marker genes, knowledge of their position in cancer progression, and the development of ever more sensitive epigenetic detection strategies, including nanotechnology approaches, are all expanding \[[@REF25], [@REF26]\]. All these landmark discoveries led to the elucidation of novel cancer biomolecular mechanisms, new scientific research tools, and the development of new epigenetic-based targeted therapeutic avenues. As a result of that, "The National Institutes of Health (NIH) Roadmap Epigenomics Mapping Consortium" is accelerating the understanding of epigenomics in human health and disease together with the ENCODE Project (ENCyclopedia Of DNA Elements) \[[@REF27], [@REF28]\]. The most immediate future of this new exciting scientific field includes the development of liquid biopsies, personalized medicine, and targeted therapies.

Although citation analysis is a useful tool with the potential benefit of insight into literature trends, it is not without limitations. Over half a century has passed since the Science Citation Index (SCI) was launched as the first systematic effort to track citations in the scientific literature \[[@REF29]\]. We recognize that citation counts have inherent biases and that they are not purely quantifiable systems to rank papers by their impact in the scientific literature. In an attempt to control for some of these inherent and potential biases, we utilized the citations per year index in addition to the total number of citations per paper. Despite that, older publications have had a longer timespan to accumulate citations giving them a distinct advantage over newer and potentially more relevant studies. Lastly, one hundred is an arbitrary number since the landmark articles in epigenetic research did not accumulate enough citations such as the paper by Gama-Sosa, Slagel, Trewyn, et al. \"The 5-methylcytosine content of DNA from human tumors\" that only had 574 citations \[[@REF30]\]. Although metrics such as citation counts do have flaws, in the current era, they also serve as one way to measure objectively impact of an article in the scientific community.

Conclusions
===========

In this study, the 100 most cited articles in cancer epigenetics were examined, and the contributions from various authors, specialties, and countries were identified. Cancer epigenetics is a rapidly growing scientific field impacting translational research in cancer screening, diagnosis, classification, prognosis, and targeted treatments. Recognition of important historical contributions to this field may guide future investigations.

The authors have declared that no competing interests exist.

Consent was obtained by all participants in this study

**Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue.

References from Table [1](#TAB1){ref-type="table"} and Table [5](#TAB5){ref-type="table"}

1\. Golub TR, Slonim DK, Tamayo P, et al.: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999, 286:531-537. 10.1126/science.286.5439.531

2\. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000, 403:503-511. 10.1038/35000501

3\. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. P Natl Acad Scad USA. 1996, 93:9821-9826. 10.1073/pnas.93.18.9821

4\. Barski A, Cuddapah S, Cui K, et al.: High-resolution profiling of histone methylations in the human genome. Cell. 2007, 129:823-837. 10.1016/j.cell.2007.05.009

5\. Hegi ME, Diserens AC, Gorlia T, et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005, 352:997-1003. 10.1056/NEJMoa043331

6\. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008, 455:1061-1068. 10.1038/nature07385

7\. Cerami E, Gao J, Dogrusoz U, et al.: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2:401-404. 10.1158/2159-8290.CD-12-0095

8\. Stupp R, Hegi ME, Mason WP, etal.: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459-466. 10.1016/S1470-2045(09)70025-7

9\. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012, 487:330-337. 10.1038/nature11252

10\. Verhaak RG, Hoadley KA, Purdom E, et al.: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010, 17:98-110. 10.1016/j.ccr.2009.12.020

11\. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature. 2011, 474:609-615. 10.1038/nature10166

12\. Gupta RA, Shah N, Wang KC, et al.: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010, 464:1071-1076. 10.1038/nature08975

13\. Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. The Lancet. 2012, 379:1245-1255. 10.1016/s0140-6736(11)61347-0

14\. Travis WD, Brambilla E, Noguchi M, et al.: International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011, 6:244-285. 10.1097/JTO.0b013e318206a221

15\. Yanaihara N, Caplen N, Bowman E, et al.: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006, 9:189-198. 10.1016/j.ccr.2006.01.025

16\. Curtis C, Shah SP, Chin SF, et al.: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012, 486:346-352. 10.1038/nature10983

17\. Neve RM, Chin K, Fridlyand J, et al.: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006, 10:515-527. 10.1016/j.ccr.2006.10.008

18\. Nielsen TO, Hsu FD, Jensen K, et al.: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10:5367-5374. 10.1158/1078-0432.CCR-04-0220

19\. Cancer Genome Atlas Research Network: Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012, 489:519-525. 10.1038/nature11404

20\. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP: CpG island methylator phenotype in colorectal cancer. P Natl Acad Scad USA. 1999, 96:8681-8686. 10.1073/pnas.96.15.8681

21\. Takamizawa J, Konishi H, Yanagisawa K, et al.: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64:3753-3756. 10.1158/0008-[5472.CA](5472.CA)N-04-0637

22\. Merlo A, Herman JG, Mao L, et al.: 5\' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995, 1:686-692. 10.1038/nm0795-686

23\. Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al.: Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013, 368:2059-2074. 10.1056/NEJMoa1301689

24\. Varambally S, Dhanasekaran SM, Zhou M, et al.: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002, 419:624-629. 10.1038/nature01075

25\. Bhattacharjee A, Richards WG, Staunton J, et al.: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. P Natl Acad Scad USA. 2001, 98:13790-13795. 10.1073/pnas.191502998

26\. Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61:3225-3229.

27\. Meissner A, Mikkelsen TS, Gu H, Wet al.: Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature. 2008, 454:766-770. 10.1038/nature07107

28\. Zhang B, Pan X, Cobb GP, Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007, 302:1-12. 10.1016/j.ydbio.2006.08.028

29\. Kandoth C, McLellan MD, Vandin F, et al.: Mutational landscape and significance across 12 major cancer types. Nature. 2013, 502:333-339. 10.1038/nature12634

30\. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999, 21:103-107. 10.1038/5047

31\. Clark SJ, Harrison J, Paul CL, Frommer M: High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 1994, 22:2990-2997. 10.1093/nar/22.15.2990

32\. Herman JG, Umar A, Polyak K, et al.: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. P Natl Acad Scad USA. 1998, 95:6870-6875. 10.1073/pnas.95.12.6870

33\. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014, 513:202-209. 10.1038/nature13480

34\. Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014, 511:543-550. 10.1038/nature13385

35\. Brennan CW, Verhaak RG, McKenna A, et al.: The somatic genomic landscape of glioblastoma. Cell. 2013, 155:462-477. 10.1016/j.cell.2013.09.034

36\. Esteller M, Garcia-Foncillas J, Andion E, et al.: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000, 343:1350-1354. 10.1056/NEJM200011093431901

37\. Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, et al.: The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013, 45:1113-1120. 10.1038/ng.2764

38\. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, Schubeler D: Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet. 2007, 39:457-466. 10.1038/ng1990

39\. Figueroa ME, Abdel-Wahab O, Lu C, et al.: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010, 18:553-567. 10.1016/j.ccr.2010.11.015

40\. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al.: Integrated genomic characterization of endometrial carcinoma. Nature. 2013, 497:67-73. 10.1038/nature12113

41\. Irizarry RA, Ladd-Acosta C, Wen B, et al.: The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009, 41:178-186. 10.1038/ng.298

42\. Herman JG, Merlo A, Mao L, et al.: Inactivation of the Cdkn2/P16/Mts1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995, 55:4525-4530.

43\. Narita M, Nunez S, Heard E, et al.: Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003, 113:703-716. 10.1016/s0092-8674(03)00401-x

44\. Herman JG, Latif F, Weng Y, et al.: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. P Natl Acad Scad USA. 1994, 91:9700-9704. 10.1073/pnas.91.21.9700

45\. Swerdlow SH, Campo E, Pileri SA, et al.: The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016, 127:2375-2390. 10.1182/blood-2016-01-643569

46\. Noushmehr H, Weisenberger DJ, Diefes K, et al.: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010, 17:510-522. 10.1016/j.ccr.2010.03.017

47\. Kane MF, Loda M, Gaida GM, et al.: Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997, 57:808-811.

48\. Weisenberger DJ, Siegmund KD, Campan M, et al.: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006, 38:787-793. 10.1038/ng1834

49\. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, Schubeler D: Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet. 2005, 37:853-862. 10.1038/ng1598

50\. Fraga MF, Ballestar E, Villar-Garea A, et al.: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005, 37:391-400. 10.1038/ng1531

51\. Fabbri M, Garzon R, Cimmino A, et al.: MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. P Natl Acad Scad USA. 2007, 104:15805-15810. 10.1073/pnas.0707628104

52\. Orom UA, Derrien T, Beringer M, et al.: Long noncoding RNAs with enhancer-like function in human cells. Cell. 2010, 143:46-58. 10.1016/j.cell.2010.09.001

53\. Kleer CG, Cao Q, Varambally S, et al.: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. P Natl Acad Scad USA. 2003, 100:11606-11611. 10.1073/pnas.1933744100

54\. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014, 507:315-322. 10.1038/nature12965

55\. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R: DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001, 61:1659-1665.

56\. International Cancer Genome Consortium, Hudson TJ, Anderson W, et al.: International network of cancer genome projects. Nature. 2010, 464:993-998. 10.1038/nature08987

57\. Costello JF, Fruhwald MC, Smiraglia DJ, et al.: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000, 24:132-138. 10.1038/72785

58\. Gaudet F, Hodgson JG, Eden A, et al.: Induction of tumors in mice by genomic hypomethylation. Science. 2003, 300:489-492. 10.1126/science.1083558

59\. Sharma SV, Lee DY, Li B, et al.: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010, 141:69-80. 10.1016/j.cell.2010.02.027

60\. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG: Inactivation of the DNA repair gene O-6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999, 59:793-797.

61\. Zuber J, Shi J, Wang E, et al.: RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011, 478:524-528. 10.1038/nature10334

62\. Iorio MV, Visone R, Di Leva G, et al.: MicroRNA signatures in human ovarian cancer. Cancer Res. 2007, 67:8699-8707. 10.1158/0008-[5472.CA](5472.CA)N-07-1936

63\. Dweep H, Sticht C, Pandey P, Gretz N: miRWalk\--database: prediction of possible miRNA binding sites by \"walking\" the genes of three genomes. J Biomed Inform. 2011, 44:839-847. 10.1016/j.jbi.2011.05.002

64\. Comijn J, Berx G, Vermassen P, et al.: The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell. 2001, 7:1267-1278. 10.1016/s1097-2765(01)00260-x

65\. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB: Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994, 7:536-540. 10.1038/ng0894-536

66\. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T: Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010, 285:17442-17452. 10.1074/jbc.M110.107821

67\. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 2006, 9:435-443. 10.1016/j.ccr.2006.04.020

68\. Carroll JS, Meyer CA, Song J, et al.: Genome-wide analysis of estrogen receptor binding sites. Nat Genet. 2006, 38:1289-1297. 10.1038/ng1901

69\. Valk PJ, Verhaak RG, Beijen MA, et al.: Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004, 350:1617-1628. 10.1056/NEJMoa040465

70\. Weinstein JN, Myers TG, O\'Connor PM, et al.: An information-intensive approach to the molecular pharmacology of cancer. Science. 1997, 275:343-349. 10.1126/science.275.5298.343

71\. Kantarjian H, Issa JP, Rosenfeld CS, et al.: Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006, 106:1794-1803. 10.1002/cncr.21792

72\. Houseman EA, Accomando WP, Koestler DC, et al.: DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinform. 2012, 13:86. 10.1186/1471-2105-13-86

73\. Patel AP, Tirosh I, Trombetta JJ, et al.: Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014, 344:1396-1401. 10.1126/science.1254257

74\. West M, Blanchette C, Dressman H, et al.: Predicting the clinical status of human breast cancer by using gene expression profiles. P Natl Acad Scad USA. 2001, 98:11462-11467. 10.1073/pnas.201162998

75\. Turchinovich A, Weiz L, Langheinz A, Burwinkel B: Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011, 39:7223-7233. 10.1093/nar/gkr254

76\. McCabe MT, Ott HM, Ganji G, et al.: EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012, 492:108-112. 10.1038/nature11606

77\. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000, 25:315-319. 10.1038/77083

78\. Turcan S, Rohle D, Goenka A, et al.: IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012, 483:479-483. 10.1038/nature10866

79\. Rhee I, Bachman KE, Park BH, et al.: DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002, 416:552-556. 10.1038/416552a

80\. Lapointe J, Li C, Higgins JP, et al.: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. P Natl Acad Scad USA. 2004, 101:811-816. 10.1073/pnas.0304146101

81\. Eckhardt F, Lewin J, Cortese R, et al.: DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet. 2006, 38:1378-1385. 10.1038/ng1909

82\. Bos PD, Zhang XH, Nadal C, et al.: Genes that mediate breast cancer metastasis to the brain. Nature. 2009, 459:1005-1009. 10.1038/nature08021

83\. Iliopoulos D, Hirsch HA, Struhl K: An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009, 139:693-706. 10.1016/j.cell.2009.10.014

84\. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K: Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006, 20:1123-1136. 10.1101/gad.381706

85\. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES: The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011, 117:5019-5032. 10.1182/blood-2011-01-293050

86\. Chapman MA, Lawrence MS, Keats JJ, et al.: Initial genome sequencing and analysis of multiple myeloma. Nature. 2011, 471:467-472. 10.1038/nature09837

87\. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K: Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006, 25:2537-2545. 10.1038/sj.onc.1209283

88\. Gregoretti IV, Lee YM, Goodson HV: Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004, 338:17-31. 10.1016/j.jmb.2004.02.006

89\. Li QL, Ito K, Sakakura C, et al.: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002, 109:113-124. 10.1016/S0092-8674(02)00690-6

90\. Ng EK, Chong WW, Jin H, et al.: Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009, 58:1375-1381. 10.1136/gut.2008.167817

91\. Bibikova M, Barnes B, Tsan C, et al.: High density DNA methylation array with single CpG site resolution. Genomics. 2011, 98:288-295. 10.1016/j.ygeno.2011.07.007

92\. Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, Gil J, Walsh MJ, Zhou MM: Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010, 38:662-674. 10.1016/j.molcel.2010.03.021

93\. Suzuki H, Watkins DN, Jair KW, et al.: Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004, 36:417-422. 10.1038/ng1330

94\. Esteller M, Silva JM, Dominguez G, et al.: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000, 92:564-569. 10.1093/jnci/92.7.564

95\. Schlesinger Y, Straussman R, Keshet I, et al.: Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet. 2007, 39:232-236. 10.1038/ng1950

96\. Shimono Y, Zabala M, Cho RW, et al.: Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009, 138:592-603. 10.1016/j.cell.2009.07.011

97\. Doi A, Park IH, Wen B, et al.: Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet. 2009, 41:1350-1353. 10.1038/ng.471

98\. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999, 59:67-70.

99\. Belinsky SA, Nikula KJ, Palmisano WA, et al.: Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. P Natl Acad Scad USA. 1998, 95:11891-11896. 10.1073/pnas.95.20.11891

100\. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, Feinberg AP: Relaxation of imprinted genes in human cancer. Nature. 1993, 362:747-749. 10.1038/362747a0
